The American Medical Association (AMA) announced an update to the Current Procedural Terminology (CPT)^® code set, to now include the Moderna COVID-19 vaccine for children ages 6 months through 5 years old. 

CPT codes clinically distinguish each coronavirus vaccine to allow for data-driven tracking, reporting and analysis that has helped streamline the public health response to the pandemic.

The provisional CPT codes will become effective if Moderna’s pediatric COVID-19 vaccine candidate is granted an Emergency Use Authorization by the U.S. Food and Drug Administration (FDA). AMA is publishing the CPT code update to ensure a smooth digital transition across the U.S. health care system in advance of the potential FDA authorization.

AMA also offers a vaccine code finder to help identify the appropriate CPT code combination for the type and dose of COVID-19 vaccine provided to each patient. This process facilitates accurate coding and reporting of COVID-19 vaccines and immunization services.

The new product code and long descriptor for the pediatric vaccine is:

• 91311:  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use

The new administration codes and long descriptors for the pediatric vaccine are:

• 0111A:  Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose
• 0112A:  Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose

For more information, please visit the AMA website.

Additional Resources:

• CMA COVID-19 Vaccine Toolkit for Physician Practices 
• CMA COVID-19 Vaccine Reimbursement Quick Guide